DOT

Identity

Manufacturer

Motif Neurotech

Model number

—unknownUpdated: 2026-05-04

Codename

XCSverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Aliases

Motif XCS System, Motif Neurotech DOTverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Generation

—unknownUpdated: 2026-05-04

Country of origin

USverifiedSource

1. Motif Neurotech — official sitehttps://www.motifneuro.tech

Updated: 2026-05-04

Released

—unknownSource

1. Investigational; not yet commercial

Updated: 2026-05-04

Announced

2026-04verifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Discontinued

—unknownUpdated: 2026-05-04

Status

clinical-trialverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Classification

Invasiveness

invasiveverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Modalities

DBSverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Primary modality

DBSverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Direction

writeverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Categories

medical-implant, stimulation, therapeuticverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Form factor

cranial-implantverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Use cases

treatment-resistant depressionverifiedSources (2)

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27
2. STAT News — Motif Neurotech FDA nodhttps://www.statnews.com/2026/04/27/motif-neurotech-gets-fda-nod-brain-implant-depression/2026-04-27

Updated: 2026-05-04

Target users

psychiatrist, patient-depressionverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Stimulation

Capable

YesverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Connectivity

Protocols

proprietary-rfverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Bluetooth

—unknownUpdated: 2026-05-04

Bluetooth profiles

—unknownUpdated: 2026-05-04

Concurrent mode

—unknownUpdated: 2026-05-04

Encryption (transit)

—unknownUpdated: 2026-05-04

Pairing methods

—unknownUpdated: 2026-05-04

Cloud sync

—unknownUpdated: 2026-05-04

Offline recording

—unknownUpdated: 2026-05-04

Power

Sources

otherverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Battery life (active)

—unknownUpdated: 2026-05-04

Charging port

—unknownUpdated: 2026-05-04

Charging time

—unknownUpdated: 2026-05-04

Battery replaceable

—unknownUpdated: 2026-05-04

Notes

Battery-less; powered by external transcutaneous wireless link during a daily session.verifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Physical

Weight

—unknownUpdated: 2026-05-04

Dimensions

—unknownUpdated: 2026-05-04

Materials

—unknownUpdated: 2026-05-04

Sizes

—unknownUpdated: 2026-05-04

Head circumference

—unknownUpdated: 2026-05-04

Operating temp

—unknownUpdated: 2026-05-04

Software & data

Mobile app

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Cloud platform

—unknownUpdated: 2026-05-04

Offline mode

YesverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Subscription required

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Raw data access

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Export formats

—unknownUpdated: 2026-05-04

LSL support

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Data ownership

manufacturerverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Apps

—unknownUpdated: 2026-05-04

SDK & developer access

Has SDK

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Open source

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Languages

—unknownUpdated: 2026-05-04

Web Bluetooth

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Raw sample access

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

BCI paradigms

—unknownUpdated: 2026-05-04

3rd-party integrations

—unknownUpdated: 2026-05-04

Docs

—unknownUpdated: 2026-05-04

Regulatory & clinical

FDA status

breakthrough-deviceverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

CE mark

NoverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Certifications

FDA Breakthrough Device, FDA IDE — RESONATE Early Feasibility StudyverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Prescription required

YesverifiedSource

1. Motif Neurotech — FDA IDE for first clinical trialhttps://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression2026-04-27

Updated: 2026-05-04

Pediatric approved

—unknownUpdated: 2026-05-04

Pricing & availability

MSRP

—unknownSource

1. Investigational — not commercially available

Updated: 2026-05-04

Current price

—unknownUpdated: 2026-05-04

Subscription

—unknownUpdated: 2026-05-04

Warranty

—unknownUpdated: 2026-05-04

Return policy (days)

—unknownUpdated: 2026-05-04

Where to buy

—unknownSource

1. Investigational — no buy URL

Updated: 2026-05-04

Editor’s take